Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 37

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53

Valente, L J, Grabow, S, Vandenberg, C J, Strasser, A, Janic, A·2016·Oncogene

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2015.457

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 37

  1. Lane DP . p53, guardian of the genome. Nature 1992; 358: 15–16. · DOI · Paper page
  2. Levine AJ . p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–331. · DOI · Paper page
  3. Vogelstein B, Lane D, Levine AJ . Surfing the p53 network. Nature 2000; 408: 307–310. · DOI · Paper page
  4. Vousden KH, Lane DP . p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275–283. · DOI · Paper page
  5. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CAJ, Butel JS et al. Mice deficient for p53 are developmentally normal but are susceptible to spontaneous tumours. Nature 1992; 356: 215–221. · DOI · Paper page
  6. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1–7. · DOI · Paper page
  7. Michalak EM, Jansen ES, Happo L, Cragg MS, Tai L, Smyth GK et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ 2009; 16: 684–696. · DOI · Paper page
  8. Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 2008; 28: 5391–5402. · DOI
  9. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533–538. · DOI · Paper page
  10. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4: 321–328. · DOI · Paper page
  11. Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57–70. · DOI · Paper page
  12. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P . Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675–684. · DOI · Paper page
  13. Newbold A, Salmon JM, Martin BP, Stanley K, Johnstone RW . The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Emu-myc model of B-cell lymphoma. Oncogene 2014; 33: 5415–5423. · DOI
  14. Patino-Garcia A, Sotillo-Pineiro E, Sierrasesumaga-Ariznabarreta L . p21WAF1 mutation is not a predominant alteration in pediatric bone tumors. Pediatr Res 1998; 43: 393–395. · DOI
  15. McKenzie KE, Siva A, Maier S, Runnebaum IB, Seshadri R, Sukumar S . Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations. Clin Cancer Res 1997; 3: 1669–1673.
  16. Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781–3784. · DOI · Paper page
  17. Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ . Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 2002; 21: 8486–8497. · DOI
  18. Topley GI, Okuyama R, Gonzales JG, Conti C, Dotto GP . p21(WAF1/Cip1) functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. Proc Natl Acad Sci USA 1999; 96: 9089–9094. · DOI · Paper page
  19. Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM . Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene 2000; 19: 5338–5347. · DOI
  20. Yang WC, Mathew J, Velcich A, Edelmann W, Kucherlapati R, Lipkin M et al. Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res 2001; 61: 565–569.
  21. Wang YA, Elson A, Leder P . Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci USA 1997; 94: 14590–14595. · DOI · Paper page
  22. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M . Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001; 61: 6234–6238.
  23. Bearss DJ, Lee RJ, Troyer DA, Pestell RG, Windle JJ . Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res 2002; 62: 2077–2084.
  24. Martins CP, Berns A . Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J 2002; 21: 3739–3748. · DOI
  25. Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G . p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci USA 2006; 103: 19842–19847. · DOI
  26. Post SM, Quintas-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G . p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene 2010; 29: 1260–1269. · DOI
  27. Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep 2013; 3: 1339–1345. · DOI · Paper page
  28. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269–1283. · DOI · Paper page
  29. Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O'Connor L, Milla L et al. An inducible lentiviral guide rna platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep 2015; 10: 1422–1432. · DOI · Paper page
  30. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM . The Eμ-myc transgenic mouse: a model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988; 167: 353–371. · DOI · Paper page
  31. Langdon WY, Harris AW, Cory S, Adams JM . The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice. Cell 1986; 47: 11–18. · DOI · Paper page
  32. Strasser A, Elefanty AG, Harris AW, Cory S . Progenitor tumours from Em-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J 1996; 15: 3823–3834. · DOI
  33. Strasser A, Harris AW, Bath ML, Cory S . Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331–333. · DOI · Paper page
  34. Nakano K, Vousden KH . PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683–694. · DOI · Paper page
  35. Jiang D, Brady CA, Johnson TM, Lee EY, Park EJ, Scott MP et al. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc Natl Acad Sci USA 2011; 108: 17123–17128. · DOI
  36. Hoffman B, Liebermann DA . Apoptotic signaling by c-MYC. Oncogene 2008; 27: 6462–6472. · DOI · Paper page
  37. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145: 571–583. · DOI · Paper page

Cited by

See all 37

Metadata

Authors
Valente, L. J., Grabow, S., Vandenberg, C. J., Strasser, A., & Janic, A.
Venue
Oncogene
Published
2015-12-07
Volume
35
Issue
29
Pages
3866-3871
ISSN
  • 0950-9232
  • 1476-5594
Cited by
37
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. https://app.cochat.ai/papers/10.1038/onc.2015.457
The paper
Valente, L. J., Grabow, S., Vandenberg, C. J., Strasser, A., & Janic, A. (2016). Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. Oncogene. https://doi.org/10.1038/onc.2015.457

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.